WHO Advises Against Use of Remdesivir on COVID Patients
The World Health Organization says the antiviral drug remdesivir is not beneficial and should not be used in treating patients hospitalized with COVID-19. A WHO panel of international experts who reviewed the results of clinical trials have concluded there currently is no evidence that remdesivir improves survival of COVID-19 patients, no matter how severely ill they are. Janet Diaz, head of Clinical Care at the World Health Organization, says the panel conditionally recommends against the use of remdesivir in hospitalized COVID-19 patients regardless of the severity of their illness. The panel says the evidence shows the drug has possibly no effect on mortality. “Now, this does not prove that remdesivir does not have a benefit at all. That is why it is a conditional recommendation. There…